FDA approval of tisagenlecleucel: Promise and complexities of a $475 000 cancer drug Journal Article

  

Authors:	Bach, P. B.; Giralt, S. A.; Saltz, L. B.
Article Title:	FDA approval of tisagenlecleucel: Promise and complexities of a $475 000 cancer drug
Keywords:	antineoplastic agents; drug approval; united states; united states food and drug administration; cancer patient; antineoplastic agent; neoplasm; neoplasms; t lymphocyte; t-lymphocytes; food and drug administration; drug development; transplantation; oncology; cancer therapy; acute lymphoblastic leukemia; drug cost; economics; drug costs; hybrid protein; recombinant fusion proteins; chimeric antigen receptor; short survey; patient counseling; drug use; drug indication; drug marketing; humans; human; priority journal; kymriah; tisagenlecleucel t
Journal Title:	JAMA - Journal of the American Medical Association
Volume:	318
Issue:	19
ISSN:	0098-7484
Publisher:	American Medical Association
Date Published:	2017-11-21
Start Page:	1861
End Page:	1862
Language:	English
DOI:	10.1001/jama.2017.15218
PUBMED:	28975266
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036542272&doi=10.1001%2fjama.2017.15218&partnerID=40&md5=aeaad0d578f9aa3784d9c15f9525c9af
Notes:	Short Survey -- Export Date: 2 January 2018 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/119538